Treatment of hypereosinophilic syndrome with imatinib mesilate

摘要: Patients with hypereosinophilic syndrome show persistent eosinophilia without recognised cause. We treated five such patients 100 mg imatinib mesilate (formerly STI-571) daily; four male normal serum interleukin 5 showed complete haematological responses; a female patient who did not respond had raised interleukin-5 concentrations. One developed leucopenia after 4 days of treatment; counts returned to when treatment was stopped. After 1 month, recurred; further for 2 days, eosinophil again became normal. All responded stopped other treatments and reduced 200 per week. This drug effectively controls in